Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- GDP/L-asparaginase in NKTL
NCT04230330Phase 1Withdrawn
- Sponsor
- National Cancer Centre Singapore
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in Extranodal NK/T-cell lymphoma (ENKTL) (2 arms), sponsored by National Cancer Centre Singapore. Primary endpoints: Overall Response Rate at 6 months and Incidence of Grade 3-5 Non-Haematological Adverse Events. Planned start Dec 2019; status: withdrawn.
02
Drugs
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT04230330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04230330.